40503-16-0

Upstream product

• 13482-22-9 4-hydroxycyclohexanone 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 2398-37-0 3-methoxyphenyl bromide 
• 365553-73-7 8-(3-methoxy-phenyl)-1,4-dioxa-spiro[4.5]decan-8-ol 

Downstream Products

• 413589-39-6 2-dimethylaminomethyl-4-hydroxy-4-(3-methoxyphenyl)-cyclohexanone 
• 40553-66-0 Methanesulfonic acid 4-(3-methoxy-phenyl)-cyclohex-3-enyl ester 
• 40503-25-1 4-m-Anisyl-cyclohex-3-en-1-ol 
• 40503-91-1 4-(3-methoxyphenyl)cyclohexan-1-one 

Relevant academic research and scientific papers

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

NOVEL PIPERIDINE DERIVATIVE

The invention provides a compound of the following formula (1): wherein m, n, and p are independently an integer of 0 - 4, provided 3 ≤ m + n ≤ 8; X is nitrogen atom or a group of the formula: C-R15; Y is a substituted or unsubstituted aromatic group, etc.; R15, R1, R2, R3, R4 , R5, R6 and R7 are hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and Z is hydrogen atom, cyano group, etc., or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits an action for enhancing LDL receptor expression, and is useful as a medicament for treating hyperlipidemia, atherosclerosis, etc.

Substituted C-cyclohexylmethylamine derivatives

Substituted C-cyclohexylmethylamine derivatives, methods for the production thereof, pharmaceuticals containing said compounds, the use of substituted C-cyclohexylmethylamine derivatives for producing pharmaceuticals, and method of pain treatment using the pharmaceuticals.

Development of a presynaptic 5-HT1A antagonist.

A new 5-HT(1A) silent antagonist 14 (5-HT(1A) IC(50)=2.2 nM) antagonizes the effects of agonists on reciprocal forepaw treading behavior, on neuronal firing in the rat dorsal raphe, and on 5-HT(1A) release in the raphe and hippocampus. While 14 alone was inactive in the social interaction paradigm, it completely reversed the social interaction activity of the serotonergic compounds (buspirone, 1, and 2).